Psychemedics

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Dallas, TX.

DHT Holdings

In this week's newsletter, we look at a company in the middle of monetizing its major asset to see what is left after the deal closes. We also review a shipping company that has built a strong margin of safety.

Small And Microcap Newsletter: DHT Holdings Financials Give It Time Until The Next Tanker Bull Market

29% YoY revenue growth in Q3, margins surge.

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

ACTON, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2021.

Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021

Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates.

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021.

Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results

Brandywine Realty

Group 1 Automotive

Nelnet

TRI Pointe Group

According to the GuruFocus All-in-One Screener, a Premium feature, as of June 28, the following companies are trading below their Peter Lynch fair values with wide margins of safety and have had positive performances over the past 12 months.

5 Undervalued Stocks Trading Below the Peter Lynch Value

MIAMI--(BUSINESS WIRE)---- $PMD--Montana Advisors issues open letter to Psychemedics CEO (Nasdaq: PMD): Dear Kubacki: It was a pleasure speaking with you two months ago via Zoom. I appreciate the time you have given me to discuss Psychemedics Corp. (PMD or the “Company”). As you know, I continue to believe that PMD shares continue to trade at a significant discount to their intrinsic value. Montana has made recommendations on ways to unlock the value of the shares, including making your balance sheet wo

Montana Advisors Writes Open Letter to Psychemedics

ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021.

Psychemedics Corporation Reports First Quarter 2021 Financial Results

ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020.

Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long- time and dedicated Psychemedics board member.

Robyn C. Davis Joins Psychemedics Board of Directors

ACTON, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Andrew Limbek has joined the Company as Vice President, Controller.

Andrew Limbek Joins Psychemedics Corporation as Vice President, Controller

ACTON, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Sarah Ashby has rejoined the company as Vice President, General Counsel.

Sarah Ashby Rejoins Psychemedics Corporation as Vice President, General Counsel

ACTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced third quarter financial results for the period ended September 30, 2020.

Psychemedics Announces Third Quarter Results

ACTON, Mass., Aug.  12, 2020  (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2020. 

Psychemedics Announces Second Quarter Results

ACTON, Mass., May  13, 2020  (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2020. 

Psychemedics Announces First Quarter Results

A New and Cost-Effective Tool to Detect and Deter Nicotine use A New and Cost-Effective Tool to Detect and Deter Nicotine use

Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA

Arena Pharmaceuticals

Cara Therapeutics

Corbus Pharmaceuticals Holdings

Cronos Group

Greenlane Holdings

GW Pharmaceuticals

Marrone Bio Innovations

New Age Beverages

Intec Parent

OrganiGram Holdings Inc.

SNDL Inc.

Tilray Brands

Therapix Biosciences

Village Farms International

Zynerba Pharmaceuticals

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Top Marijuana Stocks on the NASDAQ

ACTON, Mass., Oct.  31, 2019  (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today issued a response to a Massachusetts Supreme Judicial Court ruling in the case of Boston Police Department v. The Massachusetts Civil Service Commission, which dealt with the Boston Police Department’s 2012 decision not to hire an applicant after the applicant failed a Psychemedics Hair Test.  Previously, a Massachusetts Superior Court Judge had found that the Boston Police Department’s reliance on the test was proper.

Psychemedics Corporation Responds to Court Decision

ACTON, Mass., Sept.  19, 2019  (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, formerly known as Psychemedics Brasil Exames Toxicológicos Ltda. The new agreement replaces our prior distribution agreement with Psychemedics Brasil. As we previously disclosed, Psychemedics Brasil had a majority of its shares acquired by Instituto Hermes Pardini S.A. (IHP), a provider of medical and diagnostic services in Brazil, including reference laboratory services.

News for Psychemedics Stock (PMD)